CERo Therapeutics Financials
| CEROW Stock | 0.01 0.01 44.44% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | 1.6547 |
|
|
Investors should never underestimate CERo Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CERo Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in CERo Therapeutics Holdings.
Net Income |
|
CERo |
Understanding current and past CERo Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CERo Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in CERo Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in CERo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CERo Therapeutics Holdings. Check CERo Therapeutics' Beneish M Score to see the likelihood of CERo Therapeutics' management manipulating its earnings.
CERo Therapeutics Stock Summary
CERo Therapeutics competes with Vincerx Pharma, Viracta Therapeutics, Dogwood Therapeutics,, Viking Therapeutics, and Dyadic International. CERo Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 71902K113 |
| Older Symbol | PBAXW |
| Location | California; U.S.A |
| Business Address | 201 Haskins Way, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.cero.bio |
| Phone | 215 731 9450 |
CERo Therapeutics Key Financial Ratios
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) | ||||
| Working Capital | 5.91 M |
CERo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CERo Therapeutics's current stock value. Our valuation model uses many indicators to compare CERo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CERo Therapeutics competition to find correlations between indicators driving CERo Therapeutics's intrinsic value. More Info.CERo Therapeutics Holdings is number one stock in ebitda category among its peers. It also is number one stock in net income category among its peers . CERo Therapeutics reported EBITDA of (2.44 Million) in 2023. Comparative valuation analysis is a catch-all technique that is used if you cannot value CERo Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CERo Therapeutics Systematic Risk
CERo Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CERo Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on CERo Therapeutics correlated with the market. If Beta is less than 0 CERo Therapeutics generally moves in the opposite direction as compared to the market. If CERo Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CERo Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CERo Therapeutics is generally in the same direction as the market. If Beta > 1 CERo Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as CERo Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of CERo has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if CERo Therapeutics' financials are consistent with your investment objective using the following steps:- Review CERo Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand CERo Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare CERo Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if CERo Therapeutics' stock is overvalued or undervalued.
CERo Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CERo Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CERo Therapeutics Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of CERo Therapeutics Holdings based on widely used predictive technical indicators. In general, we focus on analyzing CERo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CERo Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 23.22 | |||
| Information Ratio | 0.1203 | |||
| Maximum Drawdown | 162.05 | |||
| Value At Risk | (39.17) | |||
| Potential Upside | 66.67 |
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.